Therapix Biosciences Ltd.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. -6.15%68.191.0%$1413.37m
BIIBBiogen, Inc. -0.76%307.711.5%$629.80m
REGNRegeneron Pharmaceuticals, Inc. 0.42%433.422.6%$527.18m
AMGNAmgen, Inc. -2.32%198.771.3%$514.18m
ILMNIllumina, Inc. 0.01%259.953.5%$395.87m
VRTXVertex Pharmaceuticals, Inc. -0.84%221.421.9%$345.49m
MRNAModerna, Inc. -11.62%23.120.0%$334.04m
ALXNAlexion Pharmaceuticals, Inc. -0.08%92.022.0%$220.54m
CODXCo-Diagnostics, Inc. -17.36%13.190.0%$204.45m
AAgilent Technologies, Inc. -1.80%76.041.6%$166.72m
EXASEXACT Sciences Corp. 0.94%81.5824.0%$165.15m
BMRNBioMarin Pharmaceutical, Inc. -0.22%89.624.3%$114.48m
INCYIncyte Corp. -2.23%74.152.5%$107.92m
SGENSeattle Genetics, Inc. 1.56%110.006.1%$107.55m
NVAXNovavax, Inc. 20.42%14.21184.0%$79.16m

Company Profile

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. It initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and BrainBright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. The company was founded on August 23, 2004 and is headquartered in Givatayim, Israel.